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Introduction
Connective tissue disease-related interstitial lung disease 
(CTD-ILD) has been described in association with many 
CTDs, including systemic sclerosis (SSc), rheumatoid 
arthritis (RA), dermatomyositis (DM) or polymyositis (PM), 
systemic lupus erythematosus (SLE), Sjögren’s syndrome 
(SjS), and mixed CTD (MCTD) (1-6). Pulmonary 
involvement can occur in many ways in CTD, but ILD 
and pulmonary hypertension are the most common 
manifestations. Thus, respiratory failure is the most 
common outcome of ILD and is a major cause of morbidity 
and mortality in CTD-ILD (3-6).
CTD-ILD is difficult to treat due to the nature of the 
underlying disease and progression to end-stage lung disease 
Original Article
Comparison of short-term outcomes for connective tissue 
disease-related interstitial lung disease and idiopathic pulmonary 
fibrosis after lung transplantation
Ji Eun Park1, Song Yee Kim1, Joo Han Song1, Young Sam Kim1, Joon Chang1, Jin Gu Lee2, Hyo Chae 
Paik2, Moo Suk Park1
1Division of Pulmonology, Department of Internal Medicine, Institute of Chest Diseases, 2Department of Thoracic and Cardiovascular Surgery, 
Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Contributions: (I) Conception and design: MS Park, JE Park; (II) Administrative support: HC Paik, JG Lee, YS Kim, J Chang; (III) Provision of 
study materials or patients: HC Paik, JG Lee, MS Park, SY Kim; (IV) Collection and assembly of data: JE Park, JH Song; (V) Data analysis and 
interpretation: JE Park, SY Kim, JH Song; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Moo Suk Park, MD, PhD. Division of Pulmonology, Department of Internal Medicine, Institute of Chest Diseases, Severance 
Hospital, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea. Email: pms70@yuhs.ac.
Background: Pulmonary involvement is common in connective tissue disease (CTD), and respiratory 
failure is a major cause of morbidity and mortality in CTD-related interstitial lung disease (CTD-ILD). 
Lung transplantation is thus important for these patients. However, survival, outcomes, and management of 
these patients after transplantation have been debated. The aim of this study was to evaluate the outcomes 
for CTD-ILD compared to those for idiopathic pulmonary fibrosis (IPF) after lung transplantation.
Methods: We performed a single-centre retrospective study of 62 patients with CTD-ILD or IPF 
who underwent lung transplantation at a tertiary hospital in South Korea between October 2012 and 
October 2016.
Results: Patients with CTD-ILD (n=15) were younger (46 vs. 60 years, P=0.001) and were less likely to be 
male (33.3% vs. 76.6%, P=0.004) than were patients with IPF (n=47). The 1-year cumulative survival rate 
was 80.0% for CTD-ILD and 59.6% for IPF (log-rank P=0.394). There was no difference in the cumulative 
survival rate (log-rank P=0.613) of age- and sex-matched patients with CTD-ILD (n=15) and IPF (n=15). 
The incidence of primary graft dysfunction was similar (P=0.154), and 2 (18.2%) patients developed possible 
CTD flare.
Conclusions: Patients with CTD-ILD and those with IPF who underwent lung transplantation had 
similar survival rates.
Keywords: Connective tissue diseases (CTD); lung transplantation; idiopathic pulmonary fibrosis (IPF); survival
Submitted Sep 16, 2017. Accepted for publication Feb 05, 2018.
doi: 10.21037/jtd.2018.02.50
View this article at: http://dx.doi.org/10.21037/jtd.2018.02.50
1547
1539Journal of Thoracic Disease, Vol 10, No 3 March 2018
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(3):1538-1547jtd.amegroups.com
that can occur despite active immunosuppressive therapy 
(1,7,8). Lung transplantation is a potentially life-saving 
treatment for patients with CTD who have progressed to 
end-stage pulmonary disease due to ILD (1,7,9-11).
However, despite the poor outcomes for CTD-ILD patients, 
lung transplantation is performed relatively infrequently in this 
population. According to data from the International Society for 
Heart and Lung Transplantation (ISHLT) registry, from January 
1995 to June 2012, CTD-associated lung disease accounted for 
only 1.3% of the 37,581 cases undergoing lung transplantation 
worldwide (12,13). Many transplantation centres do not offer 
lung transplantation to patients with CTD because of concerns 
about the nature of systemic autoimmune diseases and extra-
pulmonary involvement that might affect short- and long-term 
survival (14,15).
Survival, outcomes, and management of these patients 
after transplantation have been debated. Moreover, there 
have been few studies of CTD-ILD patients undergoing 
lung transplantation in Asia (13,16-18).
The primary objective of this study was to compare the 
post-lung transplant survival of patients with CTD-ILD 
and those with idiopathic pulmonary fibrosis (IPF), which is 
a well-established indication for lung transplantation (12). 
Secondary outcome measures included: (I) the incidence 
of primary graft dysfunction (PGD) in patients with 
CTD compared to those with IPF and (II) the pulmonary 
and extra-pulmonary recurrence of CTD after lung 
transplantation. This study is important, as it is the first 
reported comparison of patients with CTD-ILD and IPF 
undergoing lung transplantation in Asia.
Methods
Study design and population
We performed a retrospective cohort study of adults who 
underwent lung transplantation at Severance Hospital of 
Yonsei University between October 2012 and October 2016. 
We evaluated data from 128 lung transplant recipients who 
were followed through October 2017.
The diagnoses that were included as CTD-associated 
lung disorders were SSc, RA, DM, PM, SLE, SjS, and 
undifferentiated CTD (UCTD). DM and PM were 
combined into a DM/PM group.
In patients with CTD-ILD, guidelines similar to those 
of well-known interstitial pneumonia were used as the 
criteria for selecting lung transplant recipients. Patients 
with pulmonary hypertension with right ventricular failure 
worsening were also considered and this was seen in 
patients with CTD-ILD who differed from IPF patients. 
In addition, patients with CTD-ILD were associated with 
extra-pulmonary disease such as renal disease or myositis. 
Lung transplantation was performed when the disease was 
controlled by immunosuppressant medication. However, 
patients with CTD-ILD who were not controlled by 
medications had frequent underlying CTD flare ups during 
immunosuppressive therapy and were excluded. Excessive 
systemic inflammation such as vascular insufficiency and 
renal failure was also excluded.
In this study, patients requiring mechanical ventilation 
or extracorporeal membrane oxygenation (ECMO) prior 
to transplantation were excluded in order to ensure an 
accurate comparison of patients. All patients who required 
mechanical ventilation or ECMO due to respiratory failure 
prior to transplantation were only IPF patients, who were 
considered to have an effect on outcome comparisons 
between the two groups and excluded patients who 
underwent mechanical ventilation or ECMO. We also 
excluded patients who received combined organ transplants, 
such as lung-liver transplantation.
Medical records were reviewed for pre-transplant 
demographics, clinical data, immunological characteristics, 
acute rejection, complications, and survival. Pulmonary 
function test, 6-minute walk test, Echocardiogram, right 
heart catheterization, and high-resolution computed 
tomography (HRCT) were performed within 1 year before 
transplantation. Honeycomb scoring was confirmed by 
reviewing the HRCT of two pulmonologists and dividing 
the lung into six sections (upper, middle, and lower zones 
of each lung). Honeycomb score changes determined by 
visually estimating the percentage from 0% to 100% (at 5% 
intervals) and averaging them. The assessments of the two 
pulmonologists were averaged.
Clinical setting
The post-transplant immunosuppressive regimens were 
based on the protocols of the Yonsei University lung 
transplantation team. All patients were initially treated with 
a triple drug regimen consisting of a calcineurin inhibitor, 
an antimetabolite or purine synthesis inhibitor, and 
corticosteroids.
Clinical outcomes
Post-transplant data were collected from all patients, 
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including cumulative survival (at 30 days, 6 months, and 
1 year), follow-up duration, and incidences of PGD and 
CTD flare.
PGD was assessed during the first 72 hours after lung 
transplantation. The severity of PGD was graded based 
on the ratio of arterial oxygen pressure to inspired oxygen 
concentration (PaO2/FiO2) and the presence of infiltration 
on chest radiography according to the ISHLT criteria (19).
CTD flare was defined as a new or progressive condition that 
could be consistent with the underlying CTD. For all CTDs, 
symptoms of arthritis, arthralgia, myositis, muscle weakness, 
vasculitis, fever, thrombocytopenia, skin rashes, dry mouth and 
eyes, or other organ involvement consistent with the CTD 
were considered as extra-pulmonary flares. Diagnosis of CTD 
flare was based on the patient’s clinical history, assessment, and 
response to treatment. The CTD was considered more likely 
than another disease to be the cause of a flare.
Statistical analysis
Continuous variables were described using means and 
standard deviations, and categorical variables were 
described using counts and percentages. The pre-transplant 
and post-transplant characteristics of the transplant patients 
with CTD-related lung disease were compared to those of 
transplant patients with IPF using Fisher’s exact test and 
the Mann-Whitney U test for categorical and continuous 
variables, respectively. Cumulative survival was calculated 
from the time of transplantation until death, transfer, or the 
last follow-up appointment. Kaplan-Meier survival curves 
and log-rank tests were used to compare the survival of the 
two groups. To confirm an accurate survival rate comparison 
between the two groups, direct matching was performed 
using the propensity score matching method. Hazard ratios 
are expressed as relative risks (RRs) with 95% confidence 
intervals (95% CIs). Statistical analyses were performed 
using SPSS version 20 (SPSS, Inc., Chicago, IL, USA). 
A P value <0.05 was considered statistically significant.
Ethics
The study was approved by the Institutional Review Board 
(IRB) of Severance Hospital of Yonsei University, with a 
waiver of individual consent (IRB No. 4-2013-0770).
Results
A total of 128 lung transplantations were performed at 
Severance Hospital during the study period. However, 
44 patients did not have a diagnosis of CTD-ILD or 
IPF, 21 patients required ECMO and/or mechanical 
ventilation at the time of lung transplantations, and one 
patient underwent lung-liver transplantation. Therefore, 
62 patients were ultimately included in the study. Fifteen 
transplantations were performed for patients with 
CTD-ILD (11.7%), and 47 were performed for those with 
IPF (36.7%) (Figure 1).
The subtype of CTD-ILD was DM/PM in 5 patients 
(33.3%), RA in 4 (26.7%), SSc in 3 (20.0%), and SLE, SjS, 
and UCTD in 1 (6.7%) each.
The baseline characteristics and clinical variables of 
the two groups were compared (Table 1). Compared with 
patients with IPF, those with CTD-ILD were younger 
(46 vs. 60 years, P=0.001) and less likely to be male 
(33.3% vs. 76.6%, P=0.004). The mean pulmonary artery 
pressure was higher (30 vs. 24 mmHg, P=0.282) and the 
proportion of patients with pulmonary hypertension was 
higher in patients with CTD-ILD than in those with 
IPF (72.7% vs. 48.4%, P=0.291). Honeycombing score 
on HRCT was high in IPF patients (P=0.126). When 
the pulmonary function was compared, there was no 
significant difference between the two groups in forced 
vital capacity (FVC) (40% vs. 39%, P=0.911) and diffusing 
capacity (DLco) (21% vs. 25%, P=0.269). Patients with 
CTD-ILD showed a decrease in a 6-minute walk distance 
(180 vs. 210 m, P=0.388).
Endogastroduodenoscopy (EGD), chest computed 
tomography (CT) and oesophageal manometry were used 
to confirm oesophageal dysfunction. Clinically oesophageal 
dysfunction was significantly more frequent in CTD-ILD 
patients (46.7% vs. 14.9%, P=0.028), and all three patients 
who showed oesophageal dilatation on CT were CTD-ILD 
patients. Pre-transplantation laboratory data were within 
normal limits.
With respect to the donor characteristics,  age, 
sex, and body mass index were similar between both 
groups. However, PaO2 on FiO2 (P/F ratio) of 1.0 in 
CTD-ILD group was higher than in the IPF group 
(P=0.080). All patients with CTD-ILD underwent bilateral 
lung transplantation, and 10% of IPF patients underwent 
single lung transplantation, but this difference was not 
significant (P=0.323) (Table 1).
In 9 of 15 patients with CTD-ILD, pathological 
findings obtained by transplantation showed suspicious 
lung involvement of collagen vascular disease by observing 
lymphoid follicles with usual interstitial pneumonia (UIP) 
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or fibrosing non-specific interstitial pneumonia (NSIP). All 
patients with IPF were identified with UIP on lung tissue 
after transplantation, and two patients were found to have 
diffuse alveolar damage and organizing pneumonia.
In terms of the immediate outcomes after lung 
transplantation, patients with CTD-ILD had a longer 
duration of days in the intensive care unit postoperatively 
(12 vs. 8, P=0.094) and had more requirements for 
mechanical ventilators (7 vs. 5, P=0.465), but not significant 
differences. The presence of infiltrations on chest 
radiography and the P/F ratio were also similar (Table 2).
Survival was determined as of October 31, 2017. The 
median follow-up durations for CTD-ILD and IPF 
patients were 30.1 and 15.2 months, respectively (Figure 2). 
During the first 3 months, five patients with IPF (10.6%) 
died but no patients with CTD-ILD died. The 1-year 
cumulative survival rate after transplantation was 80.0% in 
CTD-ILD patients and 59.6% in IPF patients (P=0.218) 
(Figure 2). Three of the CTD-ILD patients died after 
3 months of lung transplantation. One patient underwent 
bilateral lung transplantation for RA-associated ILD 
(RA-ILD) and then right lung pneumonectomy due to 
persistent bronchopleural fistula, but eventually died of 
bacterial pneumonia with sepsis. Other patient, who also 
had RA-ILD, died of heart failure due to myopericarditis 
after lung transplantation. The last patient died of sepsis 
with gastrointestinal bleeding.
The occurrence of PGD was similar between the two 
groups. Grade 3 PGD was more common in CTD-ILD 
patients, but was not statistically significant (26.7% vs. 8.5%, 
P=0.154).
Because differences in age and sex were evident between 
the two groups, direct matching through propensity score 
matching was performed for a more accurate survival 
comparison. CTD-ILD (n=15) and age- and sex-matched 
IPF (n=15) patients were directly compared. The median 
survival durations of CTD-ILD and IPF patients were 
29.9 and 21.8 months, respectively. There were no 
differences in the cumulative survival rates of patients with 
CTD-ILD and of those IPF over the subsequent 60 months 
after transplantation (log-rank P=0.613) (Figure 3).
Two (18.2%) patients developed a possible CTD flare 
during the follow-up period. One patient was diagnosed 
with PM before transplantation and experienced subacute 
episodes with upper- and lower-extremity weakness 
and CO2 retention. The patient received steroids, 
mycophenolate mofetil as an immunosuppressive agent 
prior to transplantation, and was taking standard triple 
immunosuppressive drugs after transplantation. Nerve 
conduction velocity (NCV) and electromyography (EMG) 
were performed to distinguish the causes. The NCV 
results revealed sensorimotor polyneuropathy, and EMG 
showed generalized myopathy. We increased the dose 
of steroids, which was effective. Symptoms improved in 
128 lung transplantations performed in the Severance hospital on 
October 1, 2012, through October 31, 2016, were assessed for eligibility
62 participants underwent bilateral or single LTs from a deceased 
donor during the study period
62 included (CTD-ILD =15, IPF =47)
66 excluded: 
	44 without a diagnosis of CTD-ILD or IPF; 
 21 were receiving ECMO and/or mechanical ventilation at the time of LTs;
 1 was receiving a lung-liver transplantation
Figure 1 Flow chart of the study participants. CTD-ILD, connective tissue disease-related interstitial lung disease; IPF, idiopathic 
pulmonary fibrosis; ECMO, extracorporeal membrane oxygenation; LTs, lung transplantation.
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Table 1 Baseline characteristics of CTD-ILD and IPF patients before lung transplantation
Variables CTD-ILD (n=15) IPF (n=47) P value
Recipient
Age, median [IQR] (years) 46 [41–59] 60 [55–64] 0.001
Men, n (%) 5 (33.3) 36 (76.6) 0.004
BMI, mean ± SD (kg/m2) 21.5±3.2 21.9±3.3 0.792
Connective tissue disease, n (%)
DM/PM 5 (33.3) – –
RA 4 (26.7) – –
SSc 3 (20.0) – –
SLE 1 (6.7) – –
SjS 1 (6.7) – –
UCTD 1 (6.7) – –
Pulmonary function test
FVC, median [IQR], % predicted 40 [32–48] 39 [32–49] 0.911
DLco, median [IQR], % predicted 21 [18–32] (n=9) 25 [21–34] (n=32) 0.269
Unable to perform DLco, n (%) 6 (40.0) 15 (31.9) 0.775
6-minute walk test
6MWD, median [IQR] (m) 180 [120–250] (n=9) 210 [110–295] (n=31) 0.388
Lowest SpO2 during 6MWT, median [IQR] (%) 70 [65–79] (n=9) 77 [69–83] (n=31) 0.223
Unable to perform 6MWT, n (%) 6 (40.0) 16 (34.0) 0.760
Echocardiogram
EF, median [IQR] (%) 65 [62–71] 65 [59–68] 0.220
RVSP, median [IQR] (mmHg) 45 [38–62] (n=15) 53 [39–66] (n=32) 0.828
RVSP >40 mmHg, n (%) 10 (66.7) (n=15) 23 (71.9) (n=32) 0.742
Right heart catheterization
Mean pulmonary artery pressure, median [IQR] (mmHg) 30 [23–34] (n=11) 24 [21–29] (n=31) 0.282
Presence of PH by RHC, n (%) 8 (72.7) (n=11) 15 (48.4) (n=31) 0.291
RVSP, median [IQR] (mmHg) 45 [34–51] (n=10) 35 [27–48] (n=28) 0.317
Mean PCWP, median [IQR] (mmHg) 7 [7–11] (n=10) 10 [7–14] (n=28) 0.308
Honeycombing score on HRCT, median (IQR) 33.8 (18.0–44.0) 40.8 (31.0–51.0) 0.126
Esophageal dysfunction, n (%) 7 (46.7) 7 (14.9) 0.028
Creatinine, median (IQR) (mg/dL) 0.61 (0.50–0.70) 0.67 (0.60–0.80) 0.137
Total bilirubin, median (IQR) (mg/dL) 0.4 (0.3–0.6) 0.6 (0.4–0.7) 0.035
Table 1 (continued)
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Table 1 (continued)
Variables CTD-ILD (n=15) IPF (n=47) P value
Donor
Age, median [IQR] (years) 46 [40–55] 45 [39–50] 0.443
Men, n (%) 9 (60.0) 33 (70.2) 0.486
BMI, mean ± SD (kg/m2) 22.8±2.8 23.0±4.3 0.916
PaO2 on FiO2 of 1.0, median (IQR) 451.0 (440.0–451.0) 412.1 (357.0–500.0)  0.080
Procedure
Type of transplant, n (%) 0.323
Single 0 (0) 5 (10.6)
Bilateral 15 (100.0) 42 (89.4)
Ischemic time, mean ± SD (min) 274.3±118.8 233.1±70.5 0.374
CTD-ILD, connective tissue disease-related interstitial lung disease; IPF, idiopathic pulmonary fibrosis; BMI, body mass index; DM, 
dermatomyositis; PM, polymyositis; RA, rheumatoid arthritis; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; SjS, Sjögren’s 
syndrome; UCTD, undifferentiated connective tissue disease; FVC, forced vital capacity; DLco, diffusing capacity for carbon monoxide; 
6MWD, 6-minute walk distance; SpO2, saturation of peripheral oxygen; 6MWT, 6-minute walk test; EF, ejection fraction; RVSP, right 
ventricular systolic pressure; PH, pulmonary hypertension; RHC, right heart catheterization; PCWP, pulmonary capillary wedge pressure; 
HRCT, high-resolution computed tomography; PaO2, partial pressure of oxygen in arterial blood; FiO2, fraction of inspired oxygen.
Table 2 Outcomes of CTD-ILD and IPF patients after lung transplantations
Variables CTD-ILD (n=15) IPF (n=47) P value
Post-op ventilator day, median [IQR] (days) 7 [4–41] 5 [3–8] 0.465
ICU day, median [IQR] (days) 12 [8–34] 8 [6–12] 0.094
Post-op hospital day, median [IQR] (days) 34 [26–78] 27 [21–43] 0.118
Post-op CXR infiltration, n (%) 10 (66.7) 20 (42.6) 0.141
48-h PaO2/FiO2 ratio, median [IQR] 326 [226–390] 324 [245–384] 0.681
72-h PaO2/FiO2 ratio, median [IQR] 311 [245–348] 343 [282–380] 0.172
Primary graft dysfunction (PGD), n (%) 0.154
Grade 0 5 (33.3) 27 (57.4)
Grade 1 4 (26.7)  7 (14.9)
Grade 2 2 (13.3)  9 (19.1)
Grade 3 4 (26.7)  4 (8.5)
Months of follow-up, median (IQR) 30.1 (18.1–34.3) 15.2 (5.8–27.0) 0.053
Survival, n (%)
1 month 15 (100.0) 45 (95.7) >0.999
3 months 15 (100.0) 42 (89.4) 0.323
6 months 12 (80.0) 34 (72.3) 0.739
1 year 12 (80.0)  28 (59.6) 0.218
CTD-ILD, connective tissue disease-related interstitial lung disease; IPF, idiopathic pulmonary fibrosis; ICU, intensive care unit; CXR, chest 
X-ray; PaO2, partial pressure of oxygen in arterial blood; FiO2, fraction of inspired oxygen.
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2 weeks. The second patient with a possible flare had SLE 
and showed symptoms of dyspnoea, fever, leukopenia, 
thrombocytopenia, and hypocomplementemia. Before 
transplantation, the patient received methylprednisolone 
and hydroxychloroquine. After transplantation, the patient 
received a standard post-transplantation triple drug regimen 
and hydroxychloroquine. The patient also received a high-
dose steroid (1 mg/kg) for 2 weeks for the possible flare, and 
symptoms resolved.
Discussion
Since CTD-ILD is a systemic disease,  outcomes, 
survival, and the possibility of disease deterioration after 
transplantation have been unclear for affected patients. 
Thus relatively fewer lung transplantations have been 
performed for these patients than for patients with other 
diseases (13).
Many studies have indicated similar survival rates 
for these patient groups (13,14,16,20-26). Among the 
studies comparing the survival rates between patients 
with CTD-ILD and those with other diseases who 
underwent lung transplantation, Takagishi et al. reported 
survival outcomes for CTD patients and patients with 
chronic obstructive pulmonary disease (COPD) and 
IPF after lung transplantation. The cumulative survival 
of patients with CTD-ILD was lower than that for 
patients with COPD at 30 days, 6 months, 1, 2, 3, and 
5 years. When compared to the outcomes for IPF patients, 
cumulative survival was similar at 30 days, 6 months, 2, 3 , 
and 5 years. A significant difference in survival was only 
noted at 1 year and later (72.7% vs. 77.7%, P=0.049). The 
authors speculated that CTD-ILD and IPF patients may 
have been affected by the use of immunosuppressants, 
including steroids, prior to transplantation, unlike COPD 
patients who did not receive drugs (18). Similarly, there 
was no difference in the cumulative survival rate between 
patients with CTD-ILD and IPF in this study.
Because SSc accounts for most CTD-ILD patients, there 
have been many studies on SSc patients as a subgroup of 
CTD-ILD (14,20-26). Saggar et al. retrospectively reported 
post-lung transplantation outcomes for SSc compared 
to those for IPF. Fourteen patients with SSc and 38 with 
IPF underwent lung transplantation. The 1-year all-cause 
mortality did not differ between SSc (6.6%) and IPF 
(13.1%) patients (24). A study by Schachna et al. compared 
outcomes for SSc patients and IPF patients who underwent 
lung transplantation. Cumulative survival at 6 months after 
transplantation was 69% in the SSc group and 80% in the 
IPF group. Over the next 18 months, there was convergence 
in the survival rates such that the cumulative survival at 
2 years was similar (61% and 64%, respectively) (25).
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Figure 2 Kaplan-Meier survival curves of CTD-ILD and IPF. 
CTD-ILD, connective tissue disease-related interstitial lung 
disease; IPF, idiopathic pulmonary fibrosis.
Figure 3 Kaplan-Meier survival curves of CTD-ILD and IPF 
(age- and sex-matched, 1:1). CTD-ILD, connective tissue disease-
related interstitial lung disease; IPF, idiopathic pulmonary fibrosis.
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A contradictory result has also been reported (8,10,27). 
Bernstein et al. performed a retrospective cohort study 
of 229 adults with SSc, 201 with pulmonary artery 
hypertension (PAH), and 3,333 with ILD who underwent 
lung transplantation in the US. SSc patients showed a 
multivariable-adjusted 48% relative increase in 1-year 
mortality rate compared to non-SSc-related ILD patients 
[hazard ratio (HR), 1.48; 95% CI, 1.01–2.17). However, 
there was no difference in the 1-year mortality risk between 
patients with SSc and those with non-SSc-related PAH (HR, 
0.85; 95% CI, 0.50–1.44) (27).
Because SSc patients, who comprise a large proportion 
of CTD patients (12), were reported to have higher 
mortality rates after transplantation than ILD patients, 
fewer pulmonary transplantations have been performed for 
CTD-ILD patients due to uncertainty about the results 
after transplantation (13). Oesophageal dysmotility and 
gastroesophageal reflux disease, which are common in 
SSc patients (28), might increase the risk for infection 
and graft dysfunction (13,29-33). Therefore, CTD-ILD 
is divided into subtypes, and comparative studies with 
other diseases have been conducted. In this study, one of 
four SSc patients showed typical oesophageal dilatation 
on CT, but oesophageal dysfunction was not observed on 
manometry, and lung transplantation was conducted. After 
transplantation, there was no suspicion of bronchiolitis 
obliterans syndrome (BOS). Two patients were suspected 
of having oesophageal dilatation on CT, but could not 
undergo endogastroduodenoscopy due to their conditions. 
They survived without complications after transplantation. 
In  pat ients  with CTD-ILD, c l in ica l ly  suspected 
oesophageal dysfunction was present, but no patient showed 
complications due to esophageal dysfunction during the 
follow-up period after lung transplantation.
R e c e n t  s t u d i e s  h a v e  r e p o r t e d  t h e  r e s u l t s  o f 
transplantation for non-SSc-ILD patients (14,34). 
Courtwright et al. conducted a retrospective study of 
outcomes after transplantation in patients with non-SSc-
ILD and IPF. Non-SSc-ILD patients did not have worse 
adjusted survival rates (HR, 1.14; 95% CI, 0.92–1.42) (34).
There are also comparative studies on other subtypes of 
CTD-ILD. Yazdani et al. analysed post-transplant survival 
in RA-ILD, IPF, and SSc-ILD patients. Cumulative 
survival at 1-year post-transplantation for the RA-ILD, 
IPF, and SSc-ILD groups were 67%, 69%, and 82%, 
respectively (log-rank P=0.7). There was no significant 
difference among groups in age- and sex-adjusted analyses 
(P=0.900) (35). Ameye et al. reported their experience with 
patients with ILD associated with idiopathic inflammatory 
myopathies (IIM), such as DM or PM, who underwent 
transplantation. The 1-year survival rate was 100%, and the 
2- and 5-year survival rates were 75% compared with 86%, 
67%, and 58%, respectively, for IPF patients undergoing 
lung transplantation. Respective rates were 86%, 63%, 
and 57% for patients undergoing transplantation for non-
IPF- and non-IIM-related ILD (36). In this study, the 
median survival rate of 5 DM/PM patients (33.3%) was 
32.6 months, and one of them died of pneumonia at 
38 months postoperatively. These results together suggest 
that lung transplantation can be a valid option for RA-ILD 
and ILD-related DM/PM.
In our study, the outcomes after lung transplantation for 
CTD-ILD patients were similar to those for IPF patients 
in concurrent cohorts of transplant recipients at the same 
medical centre, even when adjusting for important factors 
such as age and sex. There were no differences in the 
cumulative survival or incidence of PGD between the two 
groups. After transplantation, two patients experienced 
possible flare of CTD, even though CTD is highly unlikely 
to flare.
This study had some limitations. First, a small number 
of patients with CTD-ILD or IPF were enrolled, and 
the analysis was conducted in one institution. Although 
this study accounts for a large distribution of lung 
transplantations performed in Asia, it is still considered as 
a relatively small-scale study worldwide. Additional multi-
centre analyses are needed. Second, the 1-year cumulative 
survival rate of IPF patients was relatively low in this study. 
Survival risk factors for IPF patients were identified as age. 
The survival rates were different between the patients under 
65 and over 65 years of age (log-rank P=0.162) (Figure 4). 
These results suggest that the survival rates of older IPF 
patients and the overall survival rates of IPF patients are low.
Third, pre-transplant right heart catheterization, 
which can accurately identify pulmonary hypertension in 
CTD-ILD patients, was not performed in all patients. 
Moreover, in a literature review, the survival rate for SSc 
varied according to the study (67.6–93.4% survival at 1-year 
post-transplantation) (14,24), but we did not analyse the 
subtypes of CTD in this study. For example, it would have 
been more accurate to identify patients with pulmonary 
hypertension who did not have ILD. Because of the 
multifactorial characteristics of the CTD disease group, 
it would be better to analyse the subtype of CTD disease. 
In addition, we reported only short-term (at 30 days, 
6 months, and 1 year) results. For a more accurate analysis, 
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including long-term complications, such as chronic lung 
allograft dysfunction, long-term survival data are needed. 
Finally, our study did not identify the factors associated 
with mortality following lung transplantation in each group 
because only three patients died. CTD-associated morbidity 
that can cause death should have been considered in the 
analysis.
However, the strength of this study is that it is the first 
to compare CTD-ILD lung transplantation recipients to 
lung transplantation recipients with other diseases in Asia. 
We confirmed the occurrence of CTD flare, but it was not 
a serious complication.
As the use of lung transplantation increases worldwide, 
lung transplantation in patients with CTD is also 
expected to increase in the future. In Asia, where there 
are still insufficient data, additional data collection, 
comparison, and analysis through prospective and 
multi-centre studies on the subgroups of CTD-ILD are 
considered necessary.
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